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Abstract: Novel strategies are needed to address vaccine hesitancy (VH), which correlates with
complementary and alternative medicine (CAM). In Switzerland, CAM providers play important
roles in vaccine counseling of vaccine hesitant (VH) parents, and traditional vaccination messaging
tends to overlook CAM provider perspectives. In the setting of a Swiss national research program
on VH, our key strategy has been to work together closely with CAM providers. To assess the
feasibility of generating educational human papillomavirus (HPV) vaccine materials that would
interest VH healthcare providers (HCPs), we invited four CAM providers to co-author two HPV
vaccine review articles for general practitioners. We conducted thematic analysis of CAM provider
comments to identify patterns that could complement and improve vaccination messaging from
CAM perspectives. We identified several themes and generated an inventory of CAM provider
messaging recommendations related to language use, presentation of background information,
nuanced statements regarding HPV vaccine efficacy and safety, and communication tools that would
be important to VH HCPs. Contrary to our initial expectations, and in an inclusive, respectful
atmosphere of open dialogue, we were able to productively finalize our manuscripts. In the
opinion of the CAM co-authors, the manuscripts effectively considered the communication needs
and perspectives of VH HCPs. Engaging with CAM providers appears to be a feasible and
innovative avenue for providing vaccine information and designing communication tools aimed at
VH healthcare providers.
J. Clin. Med. 2020, 9, 592; doi:10.3390/jcm9020592 www.mdpi.com/journal/jcm
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1. Introduction
In 2019, the World Health Organization (WHO) listed vaccine hesitancy (VH) as one of 10 major
threats to global health [1]. Understanding VH remains a puzzling challenge for clinicians and public
health authorities [2–4]. Strategies to address VH have included reinforcing traditional information
approaches focused on improving knowledge [5], clinicians using presumptive rather than participatory
communication styles [6], motivational interviewing [7], and vaccine mandates [8–10]. In response to
the WHO’s announcement about the “threat” of VH, strategies to address VH are urgently needed.
Studies show a complex association between complementary and alternative medicine (CAM)
use and VH [11], with popular narratives typically decrying CAM users and providers as categorically
anti-vaccine [12]. However, research conducted in the setting of our national research program on
VH [13,14] has suggested that providers of CAM in Switzerland are not categorically anti-vaccine.
They prefer providing individualized vaccination counseling, which includes taking time to understand
parent vaccine wishes, involving parents in vaccine decisions, and taking their vaccine concerns
seriously [15].
Not only patients are vaccine hesitant; evidence now suggests the need to address VH among
healthcare providers (HCPs) [16–18]. Based on repeated suggestions to us by Swiss CAM providers
that VH HCPs are unlikely to even read review articles that employ the traditional communication
approach that vaccines are safe and effective, we tested a strategy of listening to CAM providers’
perspectives and including them as co-authors in our review articles and communication tools for HPV
vaccines. To our knowledge, CAM providers, who play an important role in vaccination counseling in
Switzerland, have previously not been involved in similar collaborations. We hypothesized that, in
order to reach VH HCPs, it is important to use nuanced language that considers particular vaccine
concerns and communication needs. The endpoint of our collaboration was therefore to write HPV
vaccine review articles together with CAM doctors so that VH HCPs would actually read them.
Here we investigate whether an innovative approach to engaging with CAM providers is feasible
and productive. The objective of this article is to provide detailed characterizations of the insights and
lessons we learned from including four Swiss CAM doctor comments, with two as co-authors, in two
HPV vaccine review articles [19,20] written for Swiss general practitioners (both articles originally in
German, one translated to French). Overall, our findings suggest that including CAM providers in the
collaborative writing of vaccine review articles is a feasible, productive, and potentially promising
approach to design communication tools for clinical practice in order to address VH.
2. Methods
In Switzerland, CAM use is prevalent among 25%–50% of the population [21,22],
reimbursed through mandatory basic health insurance when provided by medical doctors with
additional postgraduate training and certification in anthroposophic medicine, traditional Chinese
medicine/acupuncture, phytotherapy, or homeopathy [23], and often provided by medical doctors
who have undertaken additional CAM training [24]. According to the register of medical professions
of the Swiss Federal Office of Public Health (FOPH), there are 1051 licensed medical doctors with
additional accredited CAM training [25]. However, the number of licensed medical doctors who
practice CAM or offer CAM services without full accreditation is likely higher. A representative study
of pediatricians in Switzerland reported that 23% of pediatricians had attended CM training, but only
8% had a federal certificate in one or more of these methods [26]. The same study found that 97% of
pediatrician respondents reported patients and parents inquiring about CAM, 65% were interested
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in pursuing CAM training, 16% provided CAM to their patients, and more than 50% used CAM for
themselves or their families.
Despite vaccination being on a voluntary basis and the popularity of CAM in the Swiss context,
vaccination rates for childhood vaccinations are overall relatively high for most routine childhood
vaccinations (i.e., 87%–93% nationally for 2 doses of mumps, measles, and rubella vaccine for 2-, 8-,
and 16-year-olds) [27]. However, there is high variance in HPV vaccination coverage between the
different Swiss cantons (states). Cantonal coverage ranges from 19% to 79% for two doses of the HPV
vaccine among 16-year-old females, and estimates for males are not yet available [27]. HPV vaccination
is the vaccination that has achieved lowest coverage nationally among those recommended in the
national vaccination plan [27,28].
We incorporated 4 trained CAM doctors’ comments and suggestions and included 2 of them
as co-authors on 2 HPV vaccine review articles and communication tools that we wrote for general
practitioners (GP) in Switzerland as the target audience [19,20]. One article was published, in both
German and French, in Swiss Medical Forum, a peer-reviewed journal published by the Swiss Medical
Association. In surveys, it has repeatedly been recorded as the most widely read continuing medical
education journal in Switzerland, with 39,000 copies printed per issue [29]. The other article was
published in German in Ars Medici, a popular Swiss family medicine journal, with 7500 copies printed
per issue. Our goal was to write and frame review articles with CAM providers in order to craft
messages about HPV vaccine which would be palatable also to VH HCPs while at the same time
providing medically sound, evidence-based information. The intent of both articles was to generate
tools for providers, including VH HCPs, to engage in high-quality HPV vaccine counseling, which has
been demonstrated as an important factor when addressing patient VH [30–32].
In order to provide an inside look into the discussions with our CAM doctor co-authors,
we assembled their suggestions and have subjected their comments to thematic analysis, a commonly
used, pragmatic tool allowing researchers to identify and analyze patterns in qualitative data.
We followed Braun and Clarke’s [33] suggestions regarding the 6 phases of thematic analysis: getting
familiar with the data, generating initial codes, searching for themes, reviewing themes, defining and
naming themes, and producing the report ([33], p. 87). We used the Framework Method [34] to structure
our analyses and used MAXQDA software to code and organize our data into meaningful themes.
The 4 reviewing CAM doctors included 2 pediatricians specialized in anthroposophic medicine,
a general practitioner (GP) specialized in homeopathy, and a GP of integrative family medicine. We did
not assume that they provided suggestions representative of all CAM providers, but we included
their contributions with the hypothesis that university researchers and public health authorities could
learn from CAM provider’s experiences and perspectives when generating medical review articles
and communication tools and vice versa. Of note, B.W. is a chief of pediatrics of the most renowned
Swiss hospital specializing in anthroposophic medicine, B.H. is a chief of the first center for integrative
pediatrics at a Swiss public hospital, C.G. is an influential private family medicine practitioner, and G.E.
is president of the Swiss association of homeopathic physicians and of UNION of associations of Swiss
physicians of complementary medicine.
3. Results
Through analysis of four CAM doctor recommendations for two manuscripts, we identified
several patterns, which allowed us to group data into five overarching themes related to language and
terminology, HPV vaccine efficacy, safety, communication tools for clinical consultation, and other
important points deserving elaboration. The themes are presented in detail in the Tables where we
display the specific content of CAM doctor recommendations, how we coded various sub-themes,
and if we included their recommendations in the final manuscripts.
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3.1. Language and Terminology
An overarching criticism was that the manuscripts appeared to be peddling pro-vaccination
“propaganda”, which the CAM doctors argued would be unacceptable for VH HCPs. They hypothesized
that prominent statements such as “HPV vaccine is safe and effective”, which already regularly appear
in literature published by public health authorities and in medical guidelines [35], would lead VH
HCPs to not even read the manuscripts. They recommended that we opt for nuances such as the
vaccine “is considered” to be safe and effective. Other linguistic nuances included statements that
were presented as proven facts, whereas there might be underlying uncertainty; they recommended
we state, “most experts agree”, rather than “experts agree”.
We did not follow recommendations to remove two statements that CAM doctors considered to
be “pro-vaccine propaganda”, related to vaccine efficacy in reducing genital warts, and waiting to
vaccinate until 2020 until data on vaccine efficacy in preventing cervical cancer would be available.
All agreed to underline that HPV vaccine today is well documented to reduce the incidence of cervical
dysplasia (Table 1).
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Table 1. Language and terminology.
Item Complementary and Alternative Medicine (CAM) Doctor Comments
CAM Co-Author Recommendations That We Included in
Revised Manuscripts
CAM Co-Author Recommendations That We Did Not
Include and Reasons for Not Including Them
Title
-The title (“HPV vaccine: Update 2018 for Clinical Practice”) is neutral
and therefore acceptable.
-When vaccine hesitant (VH) healthcare providers (HCPs) come across
an article entitled “HPV vaccine: safe and effective”, [35] they are likely
to not even read it because they will expect an excessively enthusiastic
pro-vaccine article, the same “government propaganda” that they have
seen over the past decades.
-An advantage of your article in the eyes of VH HCPs will be that it is not
written by authors affiliated with the Swiss Federal government.
-In the title, mention:
-The aim of the manuscript is to provide well-balanced vaccine
information.
-The individual nature of vaccine decisions.
-If you consider the statement that HPV vaccine is “safe and
effective” to be essential, at least think about the nuance that





-The CAM co-authors made comments on the following statements:
“Genital warts have essentially disappeared in countries like Australia
where high HPV vaccine coverage was achieved early on”. This might
well be correct. However, it is propaganda because at the time of HPV
vaccine introduction in Australia, this high level of vaccine efficacy was
an unproven assumption.
“Do not wait with recommending the vaccine to your patients until 2020,
when data on prevention of cancer will be available”. This is correct.
Today, however, this is “propaganda” because it is not yet known
whether the vaccine prevents cervical cancer in addition to dysplasia.
-Such statements are not needed. Concentrate on the good
pro-vaccine arguments that your article already has assembled.
-Present readers with the data that are available today so they
can reach their own conclusions.
-We did not remove this statement because we found the
effect of HPV vaccine on genital warts to be relevant.
-We did not remove the statement regarding data on cancer
prevention by HPV vaccine becoming available in 2020
because it is factually accurate, and vaccinating against HPV
will, in the meantime, lead to reductions of dysplasia cases.
Use of the term
“protection”
-Do not use the term “protection” in an indiscriminate way. Sloppy use
of language contributes to hesitancy towards vaccines and promotes the
impression of “pro-vaccine propaganda”.
-Be careful to use specific terms for specific concepts. For
example, be attentive to separate the following potential
correlates of protection:
-Documented doses of vaccine.
-Induction of antibodies.
long-term protection against dysplasia and/or cancer.
General language use
-Your statement about “optimal” vaccine counseling makes us wonder
about your intentions.
-Is the goal to reach maximal vaccination coverage in the population? Or,
is it, as CAM physicians will consider to be just as important, to help
patients reach their personal, individually selected health and
prevention goals?
-Be attentive to the formulation of the following statements:
-HPV “can cause”, rather than “causes”, cancer.
-HPV vaccination of boys “may prevent”, rather than
“prevents”, cancer.
-Prevention of genital warts via HPV vaccine “may be”, instead
of “is”, worthwhile.
-Use the word “reservations”, rather than “concerns”, about the
HPV vaccine.
-The data “suggests”, rather than “is solid”, that HPV vaccines
are safe.
-“Most experts agree”, rather than “experts agree”, that HPV
vaccines are safe.
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3.2. Vaccine Efficacy
The CAM doctors recommended we refine our discussion by highlighting that projections
regarding vaccine efficacy to protect against anal and orophyngeal cancers were hypothetical at the
time the articles were written in late 2017. Another item had to do with natural vs. vaccine-induced
antibodies. They indicated that CAM providers are generally highly interested in the body’s ability
to remove HPV and heal dysplasia after HPV acquisition by naturally induced immune responses.
The CAM doctors agreed that vaccination induces HPV-specific antibodies much more reliably and at
higher serum concentrations compared to natural infection, this being a salient argument in favor of
HPV vaccine (Table 2).
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Table 2. Vaccine Efficacy.
Item CAM Doctor Comments CAM Co-Author Recommendations That We Included into Revised Manuscripts
Protection against dysplasia vs. cancer
-Data on vaccine protection against cervical cancer is not yet available 1.
This is an important limitation to government vaccine enthusiasm.
-Emphasize that published data only support protection against cervical dysplasia at
present time and not against cancer.
-Tell the readers when data on protection against cancer is expected.
-Mention that no data yet exists to support vaccine efficacy against anal, oropharyngeal,
and other cancers.
-It is acceptable to state that experts expect vaccine to protect well also against anal and
oropharyngeal cancer, even though data is not yet available. State this as a hypothesis.
Protection against dysplasia should not be underestimated
-It is helpful to mention that a diagnosis of cervical dysplasia can be
associated with uncertainty and anxiety for many months.
-However, do not let this create the impression that the vaccine is 100% effective in
preventing dysplasia, which could lead to reduced enthusiasm for continuing to
undergo dysplasia screening at regular intervals.
-Rather, mention that HPV vaccine and dysplasia screening are complementary cancer
prevention methods for the time being.
Duration of vaccine protection
-The duration of protection is an important component of high-quality HPV
vaccine counseling.
-Hesitancy towards HPV vaccine is in part related to the fact that it is unclear
if booster doses will be necessary.
-With only 13 years of experience with HPV vaccines, it seems premature to conclude
that HPV protection is likely to last for at least 20 years. Use clear language about this,
and provide references.
-It seems premature to anticipate that vaccine protection will be lifelong. It is acceptable
to state this as speculation.
Natural vs. vaccine-induced antibodies
-Your point that HPV vaccination induces HPV antibodies much more
reliably, at higher serum concentration than “natural” HPV infection,
and that vaccine-induced antibodies are protective against future infection
with other HPV types, in contrast to naturally-induced antibodies, is
important.
-CAM providers are typically very interested in the concept that dysplasia is
a sign that the body was unable to eliminate acute HPV infection, and that,
in those with cancer, the body was unable to reverse dysplasia.
-Making such a statement is helpful to reduce HPV vaccine hesitancy among VH HCPs.
-Making this point is also important because it distinguishes immunity towards HPV
from immunity towards measles, where naturally acquired immunity persists lifelong
whereas vaccine-induced immunity may wane and cease to protect.
-The concept of the possibility of non-clearance of HPV infections and dysplasia,
respectively, are important arguments for the HPV vaccine.
1 Note that these comments were made in late 2017 when cancer prevention data was not yet available.
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3.3. Vaccine Safety
CAM doctors pointed out that our manuscripts unnecessary highlighted the local adverse
reactions to the HPV vaccine. They encouraged us to instead focus on HPV-vaccine specific safety
issues, such as case reports of rare but serious illnesses following vaccination, without inciting fear.
While commending our emphasis on large-scale epidemiological evidence, acknowledging such case
reports, they argued, would appeal to the tendency of CAM providers to incorporate “experiential”
knowledge and anecdotal evidence into their medical practices [15,36]. Finally, CAM co-authors agreed
that we point to the collective benefit of the HPV vaccine outweighing the minimal potential risks
(Table 3).
Table 3. Vaccine Safety.
Item CAM Doctor Comments
CAM Co-Author Recommendations That We
Included into Revised Manuscripts
Local adverse effects of HPV
vaccine
-You extensively discuss local adverse
reactions to HPV vaccine, even though they
are no different from other vaccines (i.e.,
pain, swelling at injection site).
-Do not let the discussion of local reactions create the
impression that you are downplaying the importance
of the long-term safety of HPV vaccine, which clearly
is more important.
Case reports of serious adverse
events following HPV vaccination
-There are case reports suggesting an
association of HPV vaccine with
auto-immune and other serious illnesses:
The link between vaccines and their
potential for triggering pre-existing
autoimmunity is an exciting field of
investigation and points to the individual
immune response to any vaccine.
-This is not unlike the well-known
association of antibiotic treatment of otitis
media with rare side effects (e.g.,
anaphylaxis to penicillin, clostridium
difficile colitis). Nobody would put into
doubt the need to use antibiotics, when they
are indicated, due to safety concerns.
Similarly, nobody would stop driving a car
for safety reasons, even though there
certainly are more deaths attributable to car
accidents than to adverse vaccine effects.
Being mindful about the rare possibility of a
car accident likely leads to more careful
driving. Being mindful about the rare
possibility of a serious adverse vaccine
reaction may lead to more careful medical
care of HPV-vaccinated persons.
-Acknowledge the existence of case reports of rare
but serious illnesses following HPV vaccination,
without using fear. Giving these case reports some
space will provide for a more well-balanced article
and will be crucial to enhance the credibility and
acceptability of your article to VH HCPs.
-Even if they are, do not dismiss these case reports as
irrelevant or inferior quality evidence. CAM
providers are more likely than biomedical physicians
to accept “experiential” types of evidence, such as
personal experiences and individual case reports. Do
not underestimate their importance.
-These case reports should not be overly dramatized,
as is currently the case in the media and via dramatic
reports by overt anti-vaxxers.
Large scale epidemiological data
suggests no serious long-term
harm of HPV vaccine
-The overall statement that HPV vaccine is a
safe vaccine is credible.
-Most VH HCPs will agree that this
large-scale epidemiological data is robust,
high-quality evidence supporting the safety
of HPV vaccine.
WHO states that after 270 million doses of
HPV vaccine administered, no signals of
any serious vaccine adverse effects have
emerged. This statement may be
counterproductive and make VH HCPs
more skeptical because these data have
been collected, in part, by vaccine
manufacturers. This reduces the
trustworthiness of the data and, therefore,
confidence in the safety of HPV vaccines.
-Consider putting these 2 concepts back to back in
the manuscript by first stating, “Rare case reports
suggest possible associations of HPV vaccine with
multiple sclerosis”.
-Follow this sentence by pointing out that large
epidemiological studies “were unable to confirm
these associations”.
-Mention that long-term safety data is in being
collected, in part, by vaccine manufacturers.
-Even large-scale epidemiological studies cannot rule
out that in rare cases, the HPV vaccine can be
harmful to an individual patient. Mention this.
-Therefore, HPV vaccine communication needs to be
appropriately balanced and circumspect, particularly
because there is no epidemiological emergency to
vaccinate the population. Mention this.
Individual risk vs. collective
benefit
Safety is a crucial aspect of any preventive
measure, particularly for the HPV vaccine
because it is now recommended for the
entire population of young men and
women.
-Mention that only a small fraction of vaccinated
persons will individually benefit because
HPV-associated cancers are overall rare.
Mention vaccine safety as an important consideration
because if everybody benefits from HPV vaccination,
it is an acceptable assumption that the benefits
outweigh the potential side effects. This will make
the manuscript more balanced and acceptable to VH
HCP readers.
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3.4. Vaccine Communication Tools for Clinical Consultation
CAM doctors suggested we “inform patients about”, as opposed to “recommending” HPV vaccine.
They also suggested that we prominently state that all vaccines remain voluntary in Switzerland and
that trusting relationships can exist between patients and physicians regardless of patient vaccination
decisions. Finally, they recommended that all patients be explicitly invited to voice concerns and
ask questions about HPV vaccine, similar to informed consent prior to any operative procedure,
even patients who state they wish to be vaccinated.
While CAM doctors pointed to how physicians can feel uneasy when broaching sexual matters,
particularly with younger adolescents, they suggested we should not “de-sexualize” HPV vaccine.
We did not follow their suggestions to include the possibility of waiting to vaccinate adolescents
until age 15–16 years (when they would be more amenable to informed HPV vaccine discussions
and decisions), which would not adhere to official recommendations to vaccinate at age 11–14 years,
prior to adolescents becoming sexually active. Similarly, we did not include the suggested possibility
of administering HPV and hepatitis B vaccines at separate times so as to attribute potential adverse
effects to each individual vaccine (Table 4).
Table 4. Vaccine communication tools for clinical consultation.
Item CAM Doctor Comments
CAM Co-Author Recommendations
That We Included into Revised
Manuscripts
CAM Co-Author Recommendations
That We Did Not Include and
Reasons for Not Including Them
The decision to
vaccinate or not to
vaccinate
-Your statement that physicians
should “patiently” and “extensively”
provide HPV vaccine information is
good.
-Your statement that physicians
should “inform” about HPV vaccine
is good, and preferable to
“recommending” the vaccine.
-For those who agreed to receive HPV
vaccine, proceeding to vaccinating
without providing the patient with
information is problematic (vaccine
consent should be treated like
pre-operative informed consent)
-Mention these points explicitly:
-Vaccination remains voluntary in
Switzerland. Doctors and patients are
free in their decision to vaccinate or
not.
-Good health and a relationship of
trust with physicians is possible for
parents and adolescents with or
without the HPV vaccine.
-Patients have a right to be informed
in a well-balanced, circumspect
manner about HPV vaccine.
-Physicians should accept and respect
patients’ personal vaccination
decisions.
-Doctors should invite patients to
voice their concerns and ask questions
about HPV vaccine even if they want




-Many physicians feel uneasy when
discussing sexual matters. This is a
main reason for poor HPV vaccine
counseling and contributes to HPV
vaccine hesitancy.
-Discussion of sexual topics requires
an adequate amount of time.
-Discussion of sexual topics with
young adolescents in the
recommended target age range (11–14
years old) makes physicians even
more uneasy.
-In general, vaccine counseling is
inadequately reimbursed.
-Placing the emphasis on
dysplasia/cancer prevention rather
than prevention of an STD is
acceptable. But do not “de-sexualize”
the HPV vaccine. This is incompatible
with an informed HPV vaccine
decision.
-Emphasize that HPV vaccination
does not obviate the need for “safer
sex” measures.
-At 15–16 years, adolescents typically
are ready for safer sex counseling.
Many CAM physicians consider that
HPV vaccine should not be given at
11–14 years but rather a few years
later. Mention this as a possibility.
-We did not increase the HPV vaccine
target age from 11–14 to 15–16 years
and retained the official
recommendation: HPV vaccine is
ideally administered prior to





-It is correct to state that the HPV
vaccine can be given at the same time
as the hepatitis B vaccine.
-Some VH HCPs and CAM providers
prefer to give HPV and hepatitis B
vaccine at different times in order for
them to be able to attribute potential
safety issues to each individual
vaccine. Mention this as a possibility.
-We did not modify our statement
because we did not find HPV and
HBV vaccine safety concerns
sufficient enough to warrant this type
of discussion.
3.5. Additional Important Items
The following points seemed particularly pertinent because they drew our attention to items
that might appeal to all readers, not just VH HCPs. For example, CAM doctors’ comments called our
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attention to the value of explicitly describing the sequence of events following natural HPV infection
in order to help build a case for the importance of primary prevention against initial HPV infection via
vaccine. Since VH is typically vaccine-specific, they encouraged us to provide more specific information
on HPV infection before discussing HPV vaccine, that we elaborate on HPV vaccination for young
men (since the recent recommendation to vaccinate boys and young men were likely not yet well
known), and that we mention the cost of HPV vaccine, including how Swiss vaccination programs are
funded, and that HPV vaccines are more expensive than other vaccines, and therefore likely lucrative
for pharmaceutical companies. Finally, they agreed on mentioning HPV herd immunity thresholds in
order to underscore the vaccine’s public health relevance (Table 5).
Table 5. Additional important items.
Item CAM Doctor Comments
CAM Co-Author Recommendations that We
Included into Revised Manuscripts
Background information on
HPV infection
-The manuscripts begin with pro-vaccine statements
about the safety and efficacy of the HPV vaccine.
This gives impression that the manuscript is
“pro-vaccine propaganda”
-A well-balanced article should begin with extensive
background information on HPV infection (natural
history, complications), rather than HPV vaccine
-Mention and underline that:
-The recommendation to vaccinate boys and young
men is not yet well known among general
practitioners, rather than stating that we “now we
need to introduce the vaccine” in young men.
-HPV infection is the most common sexually
transmitted infection.
-HPV infection is harmless (i.e., transient) in >90% of
the cases.
-Cancer is a rare complication of HPV infections.
-There are known risk factors (i.e., unprotected sex,
number of sex partners) that support individualized
HPV vaccine counseling.
-There is no antiviral therapy available. This is in fact
a pro-vaccine argument.
-The goal of HPV vaccine is protection against
dysplasia, rather than against a sexually transmitted
infection.
HPV vaccine is different
from other vaccines
-The concept that HPV vaccine is used to prevent
dysplasia and cancer stands in contrast to all other
vaccines where the goal is to prevent acute infections.
-This point once more underscores the need to
differentiate between individual vaccines when
discussing the notion of “vaccine hesitancy”,
particularly among patients who might not have
categorical attitudes towards all vaccines.
-This point is important also because, for example,
not vaccinating against measles carries a
considerable risk for the child to acquire measles,
whereas not vaccinating against HPV carries little
long-term risk, because most HPV infections are
transient and can be prevented, at least partially, by
other means (i.e., safe sex practices, fewer sexual
partners, cervical cancer screening).
-This is a point definitely worth emphasizing because
it is crucial for understanding why HPV vaccine
might be important and therefore crucial for vaccine
counseling.
-Emphasize that there is no need to use fear as a
communication strategy in order to promote the HPV
vaccine.
-It is OK to state that, similarly, there is no need by
vaccine skeptics to use fear (of serious side effects,
e.g., multiple sclerosis) to discourage vaccine.
Vaccination of boys and
young men
-The discussion of cancer at the oropharynx and anus
is important.
-This should be elaborated in order to address the
prevalent notion that the HPV vaccine is only
indicated for women.
High cost of the vaccine
-HPV vaccine is the most expensive, widely
recommended vaccine.
-The high vaccine cost puts a strain on already tight
public health budgets, even in a rich country like
Switzerland.
-The HPV vaccine is very lucrative for vaccine
manufacturers.
-The financial aspects surrounding HPV vaccine
should not be kept secret, as has been the case until
now. This secrecy is a major driver of vaccine
hesitancy
-The high cost of HPV vaccines should be discussed
appropriately. Please clarify whether taxpayer
money is being used to subsidize the vaccine.
HPV vaccine coverage of
>70% may be sufficient to
lead to herd protection in a
given population
-This is an important point. -Elaborate further with relevant references.
4. Discussion
Our collaboration with six CAM-oriented physicians has shown three main results.
First, the process of generating HPV vaccine review articles and communication tools in collaboration
with CAM providers appears feasible and may represent an important novel approach to better
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addressing VH. Second, we have generated an inventory of HPV vaccine messaging recommendations
that are likely, according to four CAM doctors, to be relevant and palatable to VH HCPs but that
may improve vaccine counseling by all HCPs. As shown in the results section, the messaging
recommendations that would likely appeal to VH HCPs and CAM provider audiences dealt
with being sensitive to language use, particularly language perceived as overtly and uncritically
“pro-vaccine”, precisions about safety and efficacy data, emphasizing vaccination as a choice in clinical
communication, and the inclusion of detailed information about HPV infections and HPV vaccine
specific information. Table 6 (below) summarizes the key strategies recommended by CAM doctors
for vaccine communication that gets vaccine-skeptical HCP on board. Third, and perhaps most
importantly, our collaboration with four reviewing CAM doctors was constructive and resulted in
messaging that was largely in favor of vaccination. This stands in contrast to popular narratives
which pigeonhole CAM users and providers as categorically anti-vaccine [12], or those who express
skepticism towards vaccination as ‘opponents’ [37].
Our collaborative approach is, to our knowledge, a first attempt of taking a CAM-inclusive
rather than CAM-exclusive vaccine messaging approach. This may seem self-evident, but it goes
beyond traditional top-down, knowledge deficit model efforts by (1) actively including VH HCPs
in the target audience for HPV review articles, (2) listening to and engaging relevant stakeholders,
(3) trying to understand the needs of the VH HCP audience, (4) targeting communication to those
needs, and (5) designing culturally targeted interventions [38]. Thomson et al. point to the need to
“understand and act upon the fact that there is no one-size fits all strategy to solve vaccine hesitancy
and that collaborative efforts are needed and must be sustained over time” ([38], p. 6458). We were
particularly impressed, despite initial skepticism on both sides, to be able to frame our reviews and
communication tools in ways that were in line with official HPV vaccine recommendations, but also
sensitive to providing HPV disease and vaccine information with nuanced language for issues where
VH HCPs might have particular degrees of skepticism and concerns. Recognizing that language
matters in healthcare [39,40], and that nuanced language choice can both empower and stigmatize
in the oft-polarized discussions around vaccination, will be important for establishing meaningful
dialogue in future efforts to address VH.
The aim of our collaboration with four CAM doctors in the design of HPV vaccine review articles
and communication tools [19,20] was to ensure that these materials would be read not only by HCPs
already favorable to vaccination, but useful particularly to the additional target audience of VH HCPs.
To our knowledge, a CAM-inclusive approach has not yet been used in creating vaccine messaging
materials for use in clinical practice. Additionally, this collaboration offers an innovative approach
seeking to address VH around HPV vaccine, which is the vaccine listed on the Swiss vaccination
schedule that has attained the lowest coverage in Switzerland [27,28]. Importantly, WHO cited
healthcare professionals as “the most trusted advisor[s] and influencer[s] of vaccination decisions” [1].
Oehler [41] recently echoed these statements in response to the recent global measles resurgence:
“New tools are needed for physicians and healthcare providers to reverse this trend and regain our
role as patient’s best advocates”. In our view, our review articles clearly benefited from CAM doctors’
emphasis on patient-oriented medicine and from their focus on building trusting relationships with
patients and families, which have been shown as important considerations for VH patients.
The work presented here suggests the feasibility of collaborative approaches that engage CAM
providers, and we recommend such innovation to other researchers and for other health care issue
and communication settings. For example, based on our productive cooperation, our research team
is now conducting focus group discussions with CAM and biomedical providers in order to design
vaccination communication interventions. We have now also successfully collaborated with the same
CAM providers on other topics during the preparation of review articles for Swiss HCPs aiming at
reducing antibiotic overuse in the setting of acute respiratory infections and asymptomatic bacteriuria
and cystitis.
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Table 6. Key general strategies recommended by 4 CAM doctors in order to improve vaccine
communication and to get vaccine-skeptical health care providers on board.
• Generate review articles on vaccines that are written by practicing doctors
# i.e., authors that are independent of the health authorities and the federal government’s
vaccine commission
• Consider that a significant proportion of health care providers are vaccine hesitant, not just patients. This
is your target audience
• Begin the articles by providing detailed background information on the infectious disease aimed to be
prevented by vaccination
# Only in a 2nd step talk about the safety and efficacy of the individual vaccine(s) available
• Discuss immunity associated with natural infection and provide comparison with immunity associated
with vaccination
• Avoid overtly pro-vaccine language
# Avoid categorically repeating that all vaccines are safe and effective
# Rather, emphasize the importance of individual patients reaching their personal, individually
selected health and prevention goals. Vaccination remains a free, individual choice in countries
that have no vaccine mandates in place, such as Switzerland
• Use precise and nuanced language
# Avoid lumping all vaccines together. Very few patients are against “vaccination” in general
# Clarify in each instance whether “protection” refers to protective antibody levels, prevention of
persistent HPV infection, dysplasia, or cancer
# Avoid stating that HPV vaccine protects against cancer before solid data is available
# Speculation (on duration of protection after vaccination, on efficacy against cancer, etc.) is
acceptable, but label it as such
# For vaccines where herd immunity plays no or a limited role, avoid discussions of herd immunity
and of a moral obligation to vaccinate
• Take vaccine safety concerns seriously
# Acknowledge the existence of rare cases of serious illnesses following vaccination
# In a second step, mention robust, large scale epidemiological vaccine safety data
• Discuss potential problems and side effects from the vaccination, discuss critical papers, alternatives
and/or the potential consequences of vaccination and non-vaccination
• Emphasize the importance of the provider investing time and effort in order for the patient to be able to
reach an informed vaccination decision
• Mention the price and financial implications of each vaccine
# Be aware of one of the major determinants of vaccine hesitancy: the prevalent perception that the
health authorities are collaborating with and/or influenced by vaccine manufacturers
On a larger scale, our ongoing National Research Program on vaccine hesitancy [13,14] has
recruited a network of more than 150 medical professionals throughout Switzerland, including
more than 40 CAM practitioners. Given the popularity and interest towards CAM of the Swiss
population [21,22] and from pediatricians [26], the incorporation of CAM perspectives and engagement
with practitioners of both CAM and biomedicine into vaccination communication strategies is, in our
view, a feasible, innovative, and reasonable approach to addressing VH in the Swiss context.
Our work has limitations. Even though the four collaborating CAM doctors were prominent CAM
practitioners in their fields, they could not possibly represent the perspectives of all CAM providers
in Switzerland, in particular the most hesitant providers. Rather, we took their recommendations by
considering them as a sounding board for the creation of messaging that they felt would overcome
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the initial hurdle of rejection by VH HCPs and also gain traction within their various networks of
CAM providers. However, we do not have data about the overall impact of the two HPV vaccine
review articles among HCPs, nor do we have data about their influence on VH among HCPs.
Such measurements go beyond the scope of this article.
Additionally, we did not integrate all CAM doctor suggestions into the final manuscripts in an
‘anything goes’ approach. Final decisions were negotiated internally with the conditions that we stay
within the realms of evidence-based medicine, we adhere to official HPV vaccine guidelines, and that
we make note of the quality of available evidence we presented in the final articles. This was possible
in the vast majority of instances.
5. Conclusions
In this article, we show that our approach to engaging with CAM providers is feasible and
productive. We have provided an inside look into an innovative approach for drafting HPV vaccine
review articles and communication tools which seem relevant to all providers, including potentially
VH HCPs. Using nuanced communication suggested to us by four CAM doctors, we were able to
develop an intervention approach with the explicit goal of addressing VH among physicians and
patients by improving the factual and communicative quality of HPV vaccine information. By inviting
CAM doctors as co-authors, we sent a symbolically strong message to practitioners of CAM in
Switzerland, indicating that we recognize their important clinical and public health role in providing
vaccine counseling, particularly to VH individuals [15,42], and that biomedicine can incorporate CAM
vaccination perspectives into materials destined for all HCPs. Through such collaboration, we have
shown how it is possible to work with individuals that popular narratives would have us believe to be
‘the opponent’ when it comes to VH [37]. Addressing VH in clinical practice can, and should, benefit
from multiple perspectives and involve all culturally relevant and appropriate stakeholders while
informing medical review articles and communication tools for HCPs.
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